Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 100%Moderate 0 · 0%High 0 · 0%

Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS

Proportion with complete resolution of a target tophus · participants with tophi in gout

Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in proportion with complete resolution of a target tophus compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 1.18 [0.7, 1.98]
1 study · 67 participants
Low

Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS

Total adverse events · participants with tophi in gout

Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 1.19 [1, 1.41]
1 study · 67 participants
Low

Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS

Withdrawals due to adverse events · participants with tophi in gout

Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 2.43 [0.51, 11.64]
1 study · 67 participants
Low

Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS

Mean sUA at end of 12 months · participants with tophi in gout

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Low